Levofloxacin is the levorotatory form of ofloxacin, and its antibacterial activity is approximately twice that of ofloxacin. It belongs to the third generation of fluoroquinolone antibacterial drugs, with wide distribution in tissues, long-lasting antibacterial effects, and high bioavailability. It is suitable for infections caused by Gram-negative bacteria, Gram-positive bacteria, and anaerobic bacteria in skin and soft tissue, respiratory system, digestive system, and urinary system.
Packaging： 400 boxes/case
Specifications： 0.2g * 14 tablets, 0.2g * 12 tablets, 0.2g * 6 tablets
Shelf Life： 24 months
Approval Number： 国药准字H20083528
Indications： In order to reduce the emergence of resistant bacteria and ensure the effectiveness of levofloxacin hydrochloride and other antibacterial drugs, levofloxacin is only used for the treatment or prevention of infections proven or highly suspected to be caused by sensitive bacteria. When selecting or modifying the treatment regimen with antibacterial drugs, the results of bacterial culture and susceptibility testing should be considered. If there is no data from these tests, empirical treatment should be based on local epidemiology and pathogen sensitivity. Bacterial culture and susceptibility testing should be performed before treatment to isolate and identify the infectious pathogens and determine their sensitivity to levofloxacin hydrochloride. Levofloxacin can be used for treatment before obtaining the above test results, and appropriate treatment methods can be selected after obtaining the test results. Like other drugs in this class, certain strains of Pseudomonas aeruginosa can quickly develop resistance when levofloxacin hydrochloride is used for treatment. During treatment, regular bacterial culture and susceptibility testing should be conducted to determine if the pathogens remain sensitive to the antibacterial drug, and to promptly detect the emergence of resistance in bacteria. Levofloxacin hydrochloride oral formulations and injectables can be used to treat mild, moderate, and severe infections in adults caused by susceptible strains of the following bacteria: 1. Hospital-acquired pneumonia; 2. Community-acquired pneumonia; 3. Acute bacterial sinusitis; 4. Acute bacterial exacerbation of chronic bronchitis; 5. Complicated skin and skin structure infections; 6. Uncomplicated skin and skin structure infections; 7. Acute bacterial prostatitis; 8. Complicated urinary tract infections; 9. Acute pyelonephritis; 10. Uncomplicated urinary tract infections; 11. Inhalational anthrax (post-exposure).
Detail
1. One of the best varieties among fluoroquinolone drugs, with strong antibacterial effects and a wide range of clinical indications.
2. High bioavailability, stable metabolism, fewer adverse reactions, and safe to use.
3. Limited competition from manufacturers with the same specifications, large market capacity, good market protection, and high profit margins.
4. Listed as a national essential drug and low-cost drug, covered by medical insurance and included in the National New Rural Cooperative Medical Scheme.
